Historical Valuation
Lisata Therapeutics Inc (LSTA) is now in the Fair zone, suggesting that its current forward PS ratio of 1964.62 is considered Fairly compared with the five-year average of -1.57. The fair price of Lisata Therapeutics Inc (LSTA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.06
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lisata Therapeutics Inc (LSTA) has a current Price-to-Book (P/B) ratio of 0.99. Compared to its 3-year average P/B ratio of 0.64 , the current P/B ratio is approximately 53.41% higher. Relative to its 5-year average P/B ratio of 0.64, the current P/B ratio is about 55.37% higher. Lisata Therapeutics Inc (LSTA) has a Forward Free Cash Flow (FCF) yield of approximately -99.81%. Compared to its 3-year average FCF yield of -87.58%, the current FCF yield is approximately 13.97% lower. Relative to its 5-year average FCF yield of -69.55% , the current FCF yield is about 43.51% lower.
P/B
Median3y
0.64
Median5y
0.64
FCF Yield
Median3y
-87.58
Median5y
-69.55
Competitors Valuation Multiple
AI Analysis for LSTA
The average P/S ratio for LSTA competitors is 331.34, providing a benchmark for relative valuation. Lisata Therapeutics Inc Corp (LSTA.O) exhibits a P/S ratio of 1964.62, which is 492.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LSTA
1Y
3Y
5Y
Market capitalization of LSTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LSTA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LSTA currently overvalued or undervalued?
Lisata Therapeutics Inc (LSTA) is now in the Fair zone, suggesting that its current forward PS ratio of 1964.62 is considered Fairly compared with the five-year average of -1.57. The fair price of Lisata Therapeutics Inc (LSTA) is between to according to relative valuation methord.
What is Lisata Therapeutics Inc (LSTA) fair value?
LSTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lisata Therapeutics Inc (LSTA) is between to according to relative valuation methord.
How does LSTA's valuation metrics compare to the industry average?
The average P/S ratio for LSTA's competitors is 331.34, providing a benchmark for relative valuation. Lisata Therapeutics Inc Corp (LSTA) exhibits a P/S ratio of 1964.62, which is 492.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Lisata Therapeutics Inc (LSTA) as of Jan 09 2026?
As of Jan 09 2026, Lisata Therapeutics Inc (LSTA) has a P/B ratio of 0.99. This indicates that the market values LSTA at 0.99 times its book value.
What is the current FCF Yield for Lisata Therapeutics Inc (LSTA) as of Jan 09 2026?
As of Jan 09 2026, Lisata Therapeutics Inc (LSTA) has a FCF Yield of -99.81%. This means that for every dollar of Lisata Therapeutics Inc’s market capitalization, the company generates -99.81 cents in free cash flow.
What is the current Forward P/E ratio for Lisata Therapeutics Inc (LSTA) as of Jan 09 2026?
As of Jan 09 2026, Lisata Therapeutics Inc (LSTA) has a Forward P/E ratio of -1.50. This means the market is willing to pay $-1.50 for every dollar of Lisata Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lisata Therapeutics Inc (LSTA) as of Jan 09 2026?
As of Jan 09 2026, Lisata Therapeutics Inc (LSTA) has a Forward P/S ratio of 1964.62. This means the market is valuing LSTA at $1964.62 for every dollar of expected revenue over the next 12 months.